This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn about the 4 fundamental investment strategies. Simplify your investing approach and make informed choices.
19,068 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Sweetgreen faced a rough spell as the market punished sweetgreen that once looked unstoppable. Now, smart investors w...
A century-old Augusta brokerage steers through consolidation by leaning into relationships, local knowledge, and a pe...
Venice AI closes a $65 million Series A led by Dragonfly at a $1 billion valuation, funding growth with equity. The m...
Meta Platforms signals a cloud compute push, aiming to sell AI capacity directly to enterprises amid a record capex c...
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
Tesla reports a robust quarter with deliveries around 515,000, topping expectations and reigniting investor optimism....
On Independence Day in the U.S., the pope travels to Lampedusa to honor migrants and commemorate lives lost, a move t...
Netflix has stumbled this year, leaving many investors wondering what comes next. This guide explains the drop, what ...
Meta Platforms is nudging into cloud computing, aiming to monetize idle compute and AI-ready infrastructure. This art...
Investors are watching whispers about Apple and Intel teaming up. This article breaks down what that could mean for s...
Paradigm-backed seed funding will accelerate M1X Global’s push to tokenize sovereign debt, starting with the Marshall...